WO2009064290A1 - Structure d'éléments de la famille tim - Google Patents

Structure d'éléments de la famille tim Download PDF

Info

Publication number
WO2009064290A1
WO2009064290A1 PCT/US2007/084601 US2007084601W WO2009064290A1 WO 2009064290 A1 WO2009064290 A1 WO 2009064290A1 US 2007084601 W US2007084601 W US 2007084601W WO 2009064290 A1 WO2009064290 A1 WO 2009064290A1
Authority
WO
WIPO (PCT)
Prior art keywords
atom
tim
thr
val
tyr
Prior art date
Application number
PCT/US2007/084601
Other languages
English (en)
Inventor
Gerardo Kaplan
Cesar Santiago
Jose M. Casasnovas
Original Assignee
Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services filed Critical Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services
Publication of WO2009064290A1 publication Critical patent/WO2009064290A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • G01N2333/10—Hepatitis A virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Definitions

  • the present invention relates to use of knowledge of the three-dimensional structure of the TIM family members in the making of agonists and antagonists of homophilic and heterophilic interactions of these receptors.
  • the structures of the TIM family members allow the design and refinement of agonist and antagonist of the interactions of TIM family receptors with viruses such as HAV and natural ligands such as IgA, semaphorin 4A, and galactin-9 for medical and veterinary purposes to prevent viral infection, regulate immune responses, modulate cell adhesion and tissue regeneration, treat and prevent cancer, and treat autoimmune and atopic diseases.
  • the structures of the TIM family members also allow the design of specific mutants with altered binding capabilities for therapeutic use.
  • T cell immunoglobulin mucin (TIM) family of type 1 integral membrane glycoproteins which contain a characteristic six-cysteine Ig-like domain extended above the cell surface by a mucin-like domain, is emerging as an important multifunctional group of receptors (22, 26, 31) that is conserved in vertebrates.
  • TTM family members are conserved in vertebrates. Indeed, mammals (bovines, porcines, canines, rodents, etc.), birds, fish, and reptiles express TIM family members.
  • the monkey Hepatitis A Virus (HAV) receptor 1 (HAVCRl) was the first identified member of the TIM family (18). Monkey and human HAVCRl are receptors for HAV (9).
  • HAVCRl is highly expressed in kidneys (18) mainly after injury (10) or in kidney tumors (42). HAVCRl is expressed in human Th2 cell lines and is associated with remission in patients with MS (19). Up to eight genes have been described in mice (Tim-1 to 8) and 3 in humans (HAVCRl /TIM-I, HAVCR2/TIM-3, and
  • TIMD4/TIM-4) 21
  • code for at least 4 cellular receptors in mice (Tim-1 , Tim-2, Tim-3 and Tim-4) and for 3 receptors in humans (TIM-I, TIM-3 and TIM-4).
  • Tim-2 is the only murine TIM member for which a human ortholog has not yet been identified.
  • Genes coding for cellular receptors of the TIM family are located in an airway hyperreactivity (AHR) regulatory locus linked to asthma and allergy susceptibility in mice (27).
  • AHR airway hyperreactivity
  • TIMs are type I cell surface glycoproteins with an N-terminal Cys-rich region followed by a mucin domain at the extracellular region, a single transmembrane region and, except in the TIM-4 receptors, a cytoplasmic tail with phosphorylation motifs.
  • Amino acid sequence identity among the N-terminal Cys-rich region of the different receptor molecules is about 40%, while between the mouse and human receptor orthologs is around 60%. There are however marked differences in the length of the threonine, serine and proline rich mucin domain, with the number of O-linked glycosylation sites ranging from 43 in Tim-4 to 1 in TIM-3 (21).
  • Tim-1 is preferentially expressed in Th2 cells and delivers a signal that enhances T-cell activation and proliferation, increasing airway inflammation and allergy (30, 39).
  • Tim-3 is mainly expressed in ThI cells and provides a negative costimulatory signal that leads to immune tolerance (34). Additionally, Tim-3 ligand binding has been related to macrophage activation and to the development of autoimmune diseases (32). Polymorphisms in Tim-1 and Tim-3 confer susceptibility to the development of asthma and allergy (27).
  • Tim-1 receptor molecules have been described for the murine members of the TIM family.
  • Crosslinking of Tim-1 receptor molecules with the 3R3 mAb activates T cells and prevents the induction of respiratory tolerance (39).
  • S-type lectin galactin-9 binding of the S-type lectin galactin-9 to glycans N-linked to the Cys-rich Ig-like domain of Tim-3 negatively regulates ThI -related autoimmunity (47).
  • Two ligands have been identified for Tim-2, Semaphorin 4A and H-ferritin (5, 23).
  • the N-terminal Cys-rich domain is involved in binding of the TIM receptors to their ligands. For instance, binding of HAV to HAVCRl/TIM-1 (38) and Tim-3 to its ligands (34, 35, 47) requires the Cys-rich region.
  • the function of the mucin domain is unclear, although it has some influence the neutralization of HAV particles by soluble HAVCRl/TIM-1 (36).
  • this receptor plays an important function in the kidney.
  • HAVCR1/TIM1 is overexpressed in the kidney (18) mainly after kidney injury (1 1) and tumor development (42). Expression of HAVCR1/TIM1 has been shown to be a marker of kidney injury (1, 10, 1 1) and kidney tumors (42).
  • HAVCRl/TIMl also known as KIM-I, kidney injury molecule 1
  • KIM-I kidney injury molecule 1
  • HAVCRl/TIMl is differentially expressed in clear cell renal cell carcinoma and blocks the differentiation of proximal tubule epithelial cells (42).
  • HAVCRl/TIMl is therefore an ideal target for therapy of kidney carcinomas as shown in an African green monkey cell model in which anti -HAVCRl /TIMl monoclonal antibody 190/4 (18) bound to immunotoxins specifically killed kidney cells expressing HAVCRl/TIMl (42).
  • FIG. 1 Crystal structures of the N-terminal Cys-rich domain of Tim- 1 and Tim- 2 receptors. Ribbon diagrams of the Tim-1 and Tim-2 structures are respectively shown in Figures IA and IB. ⁇ -strands of one face are red and those in the opposite side are pink, coil orange, 310 helix light-blue, ⁇ -helix in the BC-loop blue, while the loop between ⁇ -
  • Figure 2 Conformation of the loops connecting ⁇ -strands C and C in the Tim structures and in related IgV domains.
  • Ribbon diagram showing the GFC face of the Tim-2 ( Figure 2A) and Tim-1 ( Figure 2B) domain structures. Insets show lateral view. Residues between the two external disulphide bonds in the CC'-loop and interacting residues at the ⁇ -strands F, G and the FG-loop are yellow. Cys residues and disulphide bonds are green, while hydrogen bonds are shown as pink dashed cylinders. Oxygens and nitrogen atoms are in red and blue, respectively. Tim-1 and Tim-2 residues are labelled following Figure I D.
  • FIG. 3 N-terminal domain interactions and oligomerization of the Tim receptors. Ribbon diagrams of the two domains in the asymmetric unit of the Tim-2 ( Figure 3A) and Tim-1 ( Figure 3B) crystals. Side view of the dimer is displayed for Tim- 2, while a view along the quasi-two fold axis (2) is shown for Tim-1. Molecules presented in Figure 1 are with the same colouring scheme, while the neighbouring molecules are in yellow. Side chains of residues contributing to the dimer interfaces are included and some central residues are labelled. Acetate ligand found in the Tim-2 structure is black, water molecules are red spheres and hydrogen bonds are pink dashed cylinders. Asn residues to
  • FIG. 3C Oligomerization of the glycosylated Tim receptors with the complete extracellular region.
  • the arrows mark three Tim-2 oligomeric species. Size (IcD) and migration of the molecular weight marker is indicated.
  • Figure 3D Alignment of TIM IgV domains as in Figure ID, with residues at the dimer interface in yellow and those about the center of the interacting molecules in blue, ⁇ -strands are represented by lines. Amino acid polymorphysms in Tim-3 (green) (27) and mkTIM-1 (blue) (8) are included below the corresponding residues in the bottom of the alignment.
  • FIG. 4 Oligomerization of the Tim-2 receptor. Size exclusion chromatography of the soluble Tim-2 molecule shown in Figure 3C. Percentage of the optical density (OD) and elution volume have been plotted. The peaks for Tim-2 proteins eluting with retention volumes corresponding to monomer (M, 40 IdD), dimer (D, 80 kD) and tetramer (T, 160 IcD) are labelled. Elution of the molecular weight markers are shown with shaded lines. A representative experiment is shown.
  • FIG. Homophilic TIM-I receptor interactions in mouse and human. Binding of soluble Fc fusion proteins to plastic coated N-terminal IgV domain (Figure 5A) or the complete extracellular region of the Tim-1 receptor ( Figure 5B). Tim-Fc (Tim-1 and Tim- 2) and control ICAM-I-Fc (IC1-2D) proteins used are included in the legend. Binding at the indicated protein concentration was determined by O. D. at 492 nm (see Materials and methods). Average and standard deviation of three experiments are shown. Figure 5C.
  • Tim-l-Fc protein Normalized binding of Tim-l-Fc protein to plastic coated Tim-1/IgV in the absence (Tim- 1 ) or presence of anti-Tim- 1 (Tl .4 and Tl .10) and anti-Tim-2 (T2.1 ) mAbs, or EDTA (10 mM). Normalized binding for a mutant Hi64/Glu Tim-1 -Fc protein is also included. Average and standard deviation of 6 different measurements carried with 20 and 10 ⁇ g/ml of Fc protein are shown Figure 5D. Binding of latex beads coated with the indicated protein to cells expressing GFP, the complete TIM-1 receptor or a mutant lacking the IgV domain ( ⁇ lgV).
  • FIG. 6A Surface representation of the stable Tim-2 dimer with molecule A in pink and B in yellow. Some of the residues building up a conformational epitope at a ridge extending from the end of the CC-loop region (Arg42) in molecule A to the C'C"-loop of molecule B (Tyr50) are coloured (see also Figure 3A). Hydrophobic residues Tyr39, Ile41 and Tyr50 are orange, Arg36, His37 and Arg42 at the CC'-coil and His21 at the BC-loop are blue.
  • Tim-1 domain structure expected to be representative of the TIM receptor family. Tim-1 surface involved in the homophilic interaction is pink ( Figure 3B). Residues in a conformational epitope built by the tip of the long CC'-loop and the FG-loop onto the GFC ⁇ -sheet are coloured red and orange, respectively. In blue the surface where a polymorphism (Lys/Gln) in HAVCR 1/mkTIM-l has been mapped in the Tim-1 structure (see Figure 3D). The mutation identifies the side of the domain recognized by a mAb blocking HAV receptor binding (8).
  • FIG. 7 Crystal structures of the N-terminal Cys-rich Ig-like domain of Tim-4.
  • Figure 7A Ribbon representation of the IgV domain crystal structure of murine Tim-4. This structure is highly similar to the IgV domain described herein for Tim-1 with some differences in the BC and FG loops.
  • Figure 7B Comparison of the IgV domain structures of Tim-1 (red) and Tim-4 (blue). The BC-loop in the Tim-4 structure is quite flat compared to the same loop in Tim-1.
  • Tim-4 In FG-loop of Tim-1 the Phe has a unique conformation and extends toward the CC'-loop, in Tim-4 the same residue adopts a closed conformation (dark blue) with the side chain of the Phe residue occupying a cavity between the FG and CC loops, while in the open conformation (light blue) the Phe projects toward the top of the domain.
  • FIG. 8 Cation binding site in TIM family members: structure of the FG loop of the N-terminal Ig-like domain of Tim-4.
  • the Tim-4 structure defined a ligand binding pocket in the N-terminal IgV domain of TIMs.
  • a tartrate (TLA) ion occupies a cavity between the CC and FG loops.
  • Figure 8 A Structure of FG loop.
  • the F95 residue in the FG loop can adopt two possible configurations shown in yellow (open configuration) or pink (closed configuration).
  • Figure 8B Structure of the FG loop complexed with
  • Tim-4 was crystalized in the presence of potassium tartrate.
  • the structure of Tim-4 with the complexed salt is shown.
  • the potassium atom K in the GF loop is shown as a yellow dot, and the tartrate molecule (TLA) is shown in pink protruding from the FG loop.
  • C Sequence alignment of TIM family members denoting residues involved in the cation binding site.
  • the modeled potasium ion (K) was coordinated to the main chain oxygen atoms of V91 and G93 (marked with red asterisk) and the side chain oxygen of the conserved N96 and D97 residues (marked with blue asterisk).
  • FIG 9A Superimposed IgV structures of Tim-l(red), Tim-2 (pink) and Tim-4 (blue) as well as a model of Tim-3 (green) based on the Tim-1 crystal structure. These structures adopt a highly similar IgV domain described herein with conformational variability in BC, FG and CC loops.
  • Figure 9B Alignment of amino acid sequences of the IgV domains of TIM family members indicating positions of the BC, CC, and FG loops. The conserved six Cys residues are highlighted in green, and other conserved residues are highlighted in yellow. The N-glycosylation sites in human TIMl and TIM3 are underlined.
  • FIG. 10 Models of human TIM family members.
  • the IgV domains of the human TIM family members were modeled based on the murine Tim-1 crystal structure described herein. As shown by the superimposed HAVCR1/TIM1 (red), TIM3 (green) and TIM4 (blue) structures, the largest structural variability is at the BC-loop, where there are some differences in the loop length among the TIM gene family.
  • Figure 1 Target areas for agonists and antagonists of interactions of TIM family members.
  • Figure I IA Target areas for agonist and antagonists of homophilic and heterophilic interactions of TIM family members are marked on the surface structure of TIMl chosen as a generic TIM family member. Target areas are marked with black lines and numbered 1 to 5.
  • Figure 1 I B Alignment of sequences of murine and human TIM family members with the highlight of key residues involved in homophilic and heterophilic interactions. Residues involved in Timl-Timl homophilic interaction or Tim- 2 dimerization in cis are yellow. Residues coordinating the K ion in the Tim-4-tartrate structure are green. The K ion is coordinated to the side chain of the conserved N96 (number 99 in pdb file) and D97 (number 100 in pdb file) residues, the main chain oxygen
  • FIG. 12 Computer system comprising a memory disk 105, storing positional data of the atomic coordinates of the TIM protein, and a processor lOlgenerating a molecular model having a three dimensional shape representative of the TIM protein based on positional data.
  • the molecular model is stored in RAM 102 memory readily accessible by the processor 101.
  • FIG. 13 Homophilic Tim-1 receptor interactions. Binding of soluble Tim-1 -Fc fusion protein to 96-well plates coated Tim-1/IgV . Normalized binding of Tim-l-Fc (Tim-1) (100%) and mutant Tim-l-Fc protein where His64 was replaced by a glutamic acid (Hi64/Glu) was determined by ELISA. Average and standard deviation of 6 different measurements are shown.
  • FIG. 14 Homophilic TIM-1 receptor interactions in humans. Binding of mouse Tim-l -Fc, human TIM-I -Fc, DE-loop mutants TIM-I-Fc Arg65/Glu and DEtI containing the double mutation Asp62/His and Arg65/Glu, mouse Tim-2-Fc, or control ICAM-I -Fc (IC 1 -2D) to the complete extracellular region of human TIM-I -HA coated onto 96-well plates was monitored by ELISA.
  • Figure 15 Oligomerization of the Tim-2 receptor. Size exclusion chromatography of soluble Tim-1 (open triangles) and Tim-2 (open squares) molecules with the complete extracellular regions.
  • Tim2-BCtl corresponds to a mutant Tim-2 receptor where BC loop residues (HLG) were replaced by aligned residues in the Tim-1 BC-loop (YR). Percentage of the optical density (OD) and elution fraction are plotted. Elution fraction for the molecular weight markers are shown with shaded lines.
  • Tim-2 receptor Size exclusion chromatography of soluble Tim-1 (open triangles) and Tim-2 (open squares) molecules with the complete extracellular regions.
  • Tim2-BCtl corresponds to a mutant Tim-2 receptor where BC loop residues (HLG) were replaced by aligned residues in the Tim-1 BC-loop (YR). Percentage of the optical density (OD) and elution fraction have been plotted (see Materials and methods). Elution fraction for the molecular weight markers are shown with shaded lines. A representative experiment is shown
  • FIG. 16 Lack of binding of IgA to a TIM-1 CC'-loop mutant. The CC'-loop of TIM-1 was changed for the same loop of human TIM-4 in TIMl(Cys3-4)-Fc. Purified TIM l -Fc and mutated TIMl(Cys3-4)-Fc we captured onto anti-Fc coated 96-well plates. Binding of secretory IgA (slgA) to the captured receptors was stained using goat anti- human IgA and TMB substrate. Absorbance at 450 nm of duplicate wells was determine in an ELISA plate reader. Values are the mean absorbance and SD are shown as error bars.
  • the present invention relates to determination of the structure of the TIM receptor domains and how they bind to their ligands.
  • the previously predicted immunoglobulin superfamily (IgSF) fold for the N-terminal Cys-rich domain is further verified, including the unusually high number of conserved Cys residues (six) for a single IgSF domain.
  • the structure of the Cys-rich region for several TIM receptors is determined.
  • the crystal structures of the N-terminal domains of murine Tim-1, Tim-2, and Tim-4 were determined, and a model for murine Tim-3 was developed beased on these structures.
  • Models of the human TIM family members HAVCR 1/TIM 1 , TIM3, and TIM4 were developed based on the structures of the murine TIM family members.
  • the invention provides the first structural view of ligand-binding domains in the TIM gene family.
  • the structures of TIM family members described herein indicated that the Cys-rich Ig-like domain of HAVCR1/TIM1 forms homophilic interactions in trans that are stabilized by the mucin domain.
  • the homophilic interactions of HAVCR1/TIM1 were corroborated using techniques of immunology and biochemistry in data presented in this
  • Tim-1 , Tim-2, and Tim-4 display striking differences in oligomerization and presentation of ligand-binding epitopes, which explain the reported divergence in ligand recognition.
  • the structures and derived functional data define three distinct ligand-recognition modes in the receptor family and identify a novel TIM-TIM adhesion interaction conserved in mice and humans. Tim-1 forms homophilic interactions in trans, Tim-2 forms dimers in cis, and Tim-4 does not form homophilic interactions.
  • the model for Tim-3 also shows the formation of homophilic interactions.
  • the models of the human TIM family members HAVCR1/TIM1 , TIM3, and TIM4 resemble the structures of the corresponding murine orthologs.
  • Tim-1 , Tim-2, and Tim-4 proteins can be used to model the proteins for the design of compounds that interact with these proteins to modulate or mimic the activity of their natural, physiological ligands, or to antagonize or increase homophilic or heterophilic interactions of the proteins.
  • Various methods for molecular modelling of proteins and use of such models to design interacting molecules are known in the art. See, for example, U.S. Patents 6,845,328, 6,947,845 (relating to three dimensional modelling of compounds interacting with ribosomes) and 6,947,847 and 7,070,936 (relating to rational drug design generically) and 7,065,453 (related to analysis of combinatorial libraries).
  • one embodiment of the present invention comprises a computer system comprising a memory, e.g. disk 105, storing positional data of the atomic coordinates of the TIM protein, and a processor l O l generating a molecular model having a three dimensional shape representative of the TIM protein based on positional data.
  • a computer system comprising a memory, e.g. disk 105, storing positional data of the atomic coordinates of the TIM protein, and a processor l O l generating a molecular model having a three dimensional shape representative of the TIM protein based on positional data.
  • the method described herein utilizes computers to model receptor binding sites and to provide information, based upon physical and chemical considerations, on the suitability of a given molecule to fit within a given receptor binding site.
  • a host of computer programs are available commercially and are suitable for use in the present invention.
  • the "GrowMol" program is capable of generating organic structures that are both spatially and chemically complementary to a mathematically-defined receptor binding site.
  • the program mathematically constructs molecules, one atom at a time, to occupy the mathematically-defined space of a binding site.
  • the "GrowMol” program can be used to generate chemical structures whose physical and chemical properties are complementary to the receptor binding site.
  • the position and type of atom to be added to the model are randomly selected using Boltzmann statistics, in an effort to bias acceptance toward atoms that can form favorable interactions with the binding site.
  • the program can be obtained from a number of university sources, including from
  • the program aids in visualizing molecules and in designing lead drug compounds.
  • the "Flo” program is available online at uwmml.pharmacy.wisc.edu/Flo/ floindx.html.
  • the "Flo” program is also marketed commercially through Thistlesoft
  • the "Advanced Computation” program provides a wide range of tools for conformational analysis, including calculations that enumerate all possible torsional states of a molecule or identify just its low-energy conformations.
  • the "AMPAC” program calculates structures and electronic properties of molecules using semi-empirical quantum mechanical methods.
  • the "COMFORT” program performs conformational analyses of drug-sized molecules to identify the global minimum energy conformer, all local minima within a user-specified energy range, or a maximally diverse subset of conformers.
  • the "Advanced Computation” program provides a wide range of tools for conformational analysis, including calculations that enumerate all possible torsional states of a molecule or identify just its low-energy conformations.
  • the "AMPAC” program calculates structures and electronic properties of molecules using semi-empirical quantum mechanical methods.
  • the "COMFORT” program performs conformational analyses of drug-sized molecules to identify the global minimum energy conformer, all local minima within a user-specified energy range, or a maximally diverse subset of conformers.
  • the "MM3(2000)” program is a molecular mechanics program that produces high- quality three-dimensional structures and computes molecular energy, vibrational spectra, and a variety of thermodynamic and spectroscopic quantities.
  • the "MOLCAD” program creates and displays molecule surfaces onto which it maps key properties, including Iipophilicity, electrostatic potential, hydrogen bonding sites, and local curvature.
  • the SYBYL/Base program includes a comprehensive suite of sub-programs for molecular modeling, including structure building, optimization, and comparison; visualization of structures and associated data; annotation, hardcopy and screen capture capabilities; and a wide range of force fields.
  • BENCHWARE is a suite of software for molecular designs, visualization and
  • Accelrys Inc. (San Diego, Calif.), a subsidiary of Pharmacopeia Inc., is another commercial supplier of suitable molecular modeling software for use in the present invention. Accelrys' "QUANTA” program can be used for processing of X-ray data, electron density fitting, and model building; the "CNX” program can be used for phasing and refining of the initial X-ray model. IfNMR data are available for a receptor-ligand complex, Accelrys' "FELIX” and “Insight II” NMR modules can be used for spectral data processing, and for refining and evaluating putative structures and conformations.
  • the present invention also encompasses methods for identifying putative ligands or antagonists of the homophilic interactions of human TIM family members HAVCR1/TIM1, TIM3, and TM4, and for identifying mimetics or antagonists of the IgA ligand of HAVCRl /TIM-I .
  • the present invention also encompasses methods for identifying antagonists of the binding of Hepatitis A Virus to HAVCRl/TIM-1.
  • the present invention also encompasses methods for identifying agonists of homophilic and heterophilic interactions of human TIM family members.
  • the structures and methods described herein allows the modeling of TIM family members from different vertebrates, which can be used to identify ligands of TIM family members that have agonistic or antagonistic activity and could be used for veterinary purposes.
  • mimetics or antagonists would be useful in prevention or treatment of allergy or atopic diseases, or for prevention or treatment of autoimmune diseases.
  • a ligand that mimics the binding of HAV to HAVCRl/TIM-1 would be useful for preventing and treating HAV infection and hepatitis A.
  • Ligands that prevent homophilic or heterpophilic interactions of HAVCRl/TIMl would be useful to treat and prevent kidney tumor formation and metastasis.
  • Ligands of HAVCR1/TIM1 will be useful in preventing and treating asthma and other allergic diseases.
  • a ligand that blocks the activity of IgA ⁇ binding to HAVCRl/TIM-1 would be expected to be useful in preventing the activation of antigen presenting cells (APCs) conversely a ligand that mimics the activity of IgA ⁇ binding HAVCRl/TIM-1 would be useful for activating APCs.
  • APCs antigen presenting cells
  • ligands of TIM3 would be useful in preventing and treating autoimmune diseases.
  • Putative peptide ligands, mimetics or antagonists identified by the computer-aided design methods described above can be synthesized and tested in binding assays, e.g. as described herein in Example 2, to confirm binding biochemically.
  • Variants can be made by, e.g. phage display methods known in the art.
  • the various evolutionary methods known in the art, e.g. SELEX, for selection of peptides with high affinity binding can also be applied.
  • a method for making mutations in a TIM family member can comprise i) selecting a portion of the IgV region of a TIM family member protein that is involved in homophilic, heterophilic or ligand binding as desired, ii) performing site-directed mutation of DNA encoding the IgV region of the
  • TIM family member to obtain a mutated DNA encoding the IgV region of the TIM family member, and iii) expressing the mutated DNA in a host cell to obtain the mutated TIM family member protein.
  • the effect of the mutation on activity of the TIM family member protein could be assessed by expressing the mutated DNA encoding the IgV region of the TIM family member in an appropriate host cell and then testing the expressed protein for alteration of homophilic, heterophilic or ligand binding as desired.
  • the site- directed mutation of the TIM family member protein can be obtained by any method as known in the art, for example using a mutagenic oligonucleotide in a polymerase-chain reaction based mutagenesis method.
  • one or more of the following IgV portion of the TIM proteins is
  • INCORPORATED BY REFERENCE selected: a. Area 1 : defined by CC and FG loops. TIM-TIM interactions via the FG loop can be modified by mutating the FG loop directly and/or the CC loop that interact with the FG loop. b. Area 2: defined by BC and FG loops. Both loops are required for TIM- TIM interactions as defined by the crystal structures (Fig 3). c. Area 3: defined by the BED B-sheet and adjacent loops. The long FG loop interacts with this region if it is not fixed to the CC loop by a compound locking the cavity formed by the FG and CC loops (area 1). This area is where homophilic interactions occur. d.
  • Area 4 the channel defined by the ⁇ -strand A at the bottom, the ⁇ -strand G at one side, and the ⁇ -barrel edge at the other side. On top, the channel is limited by the BC and FG loops. A mucin tail is likely to bind to this channel. The mucin stabilizes TIM-TIM interactions.
  • one or more of the following IgV portion of the TIM proteins should be considered: a) Area 1 : defined by CC and FG loops. Binding of cations such as Ca++ and K+ and binding of potasium tartrate in Tim-4. This cavity is similar to one found in lectins that allows binding of sugars. This cavity can accommodate binding of a small molecule that could modulate binding of natural ligands, such as IgA to TIM-I , by restricting movement of FG loop needed for homophilic and heterophilic interaction as well as ligand binding.
  • This surface is also the binding site for HAV (protective mAb 190/4 binds to the blue spot shown in Figure 1 IA).
  • Area 2 defined by BC and FG loops. This is a binding area for natural ligands such as semaphorin 4A to Tim-2.
  • Area 3 defined by the BED B-sheet and adjacent loops. The long FG loop interacts with this region if it is not fixed to the CC loop by a compound locking the cavity formed by the FG and CC loops (area 1). This area is where homophilic interactions occur and is available for heterophilic and
  • Area 4 the channel defined by the ⁇ -strand A at the bottom, the ⁇ -strand G at one side, and the ⁇ -barrel edge at the other side. On top, the channel is limited by the BC and FG loops. A mucin tail is likely to bind to this channel. The mucin stabilizes homophilic interactions, and plays a similar role in heterophilic and ligand binding interactions.
  • Area 5 defined by the CC" loop (in green). This is the binding site for natural ligands such as galactin-9 in Tim-3.
  • EXAMPLE 1 DETERMINATION OF THE CRYSTAL STRUCTURE OF THE EXTRACELLULAR DOMAINS OF Tim-1, Tim-2, and Tim-4
  • Anti-Tim mAbs were obtained from eBioscience, Inc.
  • the full-length cDNA coding for Tim-1 was obtained from mouse EST #AA547594 derived from a Knowles Solter mouse 2-cell embryo cDNA library (IMAGE consortium, ATCC).
  • the cDNA coding for full-length Tim-2 was obtained from EST #AA509542 derived from a C57BL/6J mouse mammary gland cDNA library (IMAGE consortium, ATCC).
  • the cDNA of Tim-4 was also obtained from a library developed and characterized by the IMAGE consortium.
  • Tim-1 , Tim-2, and Tim-4 crystallization and structure determination [0052] Plate-like crystals of about 300 ⁇ m were initially raised with the Tim-2 protein at 12 mg/ml by the hanging drop method and with crystallization condition having 30% PEG-2000 methylether, 5% PEG-400, 0.2M ammonium sulphate, 0.1 M sodium acetate pH 4.6 and about 4% 1 ,2,3 heptanetriol.
  • the Tim-2 crystals belong to the monoclinic C2 space group, they have two molecules in the asymmetric unit and 45% solvent content.
  • Se- Met derivatized Tim-2 protein in bacteria (40) was crystallized under conditions similar to those used to crystallize the native Tim-2.
  • Tiny plate-like crystals (50 ⁇ m) were raised with the Tim-1 protein domain using crystallization conditions similar to those used for Tim-2.
  • the crystals belong to the orthorhombic P212121 space group, have two independent molecules in the asymmetric unit and about 37% solvent content.
  • Diffraction data were processed with XDS (17) and scaled with SCALA (6). Details on structure determinations are presented in Supplementary Materials and methods. Final structure resolution was achieved by several cycles of manual model rebuilding and refinement with CNS (2).
  • the current refined models contain all 1 16 amino acid residues of the Tim-1 protein construct and all 1 15 amino acid residues of the crystallized Tim-2 protein for molecule B, while the five N-terminal and the three C-terminal residues are missing for molecule A of Tim-2 (PDB files are provided as Appendix I). All residues are in allowed regions of Ramachandran plots.
  • the N-terminal residue of Tim-1 in the Figure I D corresponds to Tyr4 in the Pdb file.
  • the determined N-terminal His residue for the mammalian expressed Tim-2 receptor protein corresponds to His4 in the Pdb file. Buried surface in the Tim-1 and Tim-2 dimers were determined with the CCP4 program package (6) using a probe radius of 1.4. Ribbon figures were prepared with the program
  • Tim-4 INCORPORATED BY REFERENCE (RULE 20.6) RIBBONS (3), while the stereo views and the molecular surfaces were done with PYMOL (http://www.pymol.org). The structure of Tim-4 was obtained and analyzed as described for Tim- 1.
  • X-ray crystallography was used to determine the structure of the N-terminal Cys- rich domain of TIM family members. Functional domains of the Tim-1 and Tim-2 receptors were expressed using bacterial expression systems and crystals diffracting at high resolution were obtained. The crystal structure of the N-terminal Cys-rich region of Tim-2 was solved first by the SIRAS method at 1.5 A resolution, while the Tim-1 structure was subsequently determined to a resolution of 2.5 A. The structures revealed an IgSF domain belonging to the V set (IgV), related to the N-terminal domains of the CD4 and CAR (coxsackievirus and adenovirus receptor) cellular receptors (highest Z score in DALI search) (12).
  • IgSF domain belonging to the V set IgV
  • CD4 and CAR coxsackievirus and adenovirus receptor
  • Tim Cys-rich domains have two antiparallel ⁇ -sheets with particularly short ⁇ -strands B, E and D in one face (BED ⁇ -sheet) and the A, G, F, C, C and C" ⁇ -strands in the opposite one (GFC ⁇ -sheet) (Figs. IA, IB).
  • a distinctive Pro residue found prior the first Cys in all TIM receptor domains is responsible of the short length of the ⁇ -strand B (Fig. I D), which differentiates the ⁇ -strands in the BED face from those in the GFC ⁇ -sheet.
  • the first and last Cys residues in the N-terminal domain of the TIM receptors bridge the ⁇ -sandwich as in most IgSF domains, while the other four Cys residues characteristic of the TIM family form two external disulphide bonds that link the long CC'-loop to the GFC ⁇ -sheet (Fig. 1).
  • Tim-1 and Tim-2 N-terminal domains share 66% sequence identity and high structural similarity (Fig, 1 C).
  • the r.m.s. deviation between the two structures is 0.9 A, while the deviation between the two molecules in the asymmetric unit of the crystals is about 0.5 A.
  • the alignment of the Tim-1 and Tim-2 structures showed just three misaligned regions (Fig. 1C, ID): the BC and FG loops, and the inter-disulphide region of the CC'-loop.
  • the Tim-1 BC loop is one residue shorter than the Tim-2 loop and it does not have a helical conformation.
  • the extended and hydrophobic Tim-1 FG-loop structure is more representative of the family than that of Tim-2 (Fig. ID).
  • Tim-2 CC'-loop remains flexible and poorly defined in the electron density maps.
  • Tim-1 the conformation of the CC'-loop tip is fixed by interactions with the Arg88 and Lys99 residues at the ⁇ -strands F and G, respectively (Fig. 2B). Their side chains hydrogen bond to main chain oxygen atoms of Pro35, Ser36 and Ala38 in the two molecules of the asymmetric unit. So, the disulphide bridged CC'-loop is additionally linked to the upper half of the ⁇ -sheet by the conserved Arg88 and Lys99 residues in the Tim-1 structure. These basic residues are conserved in all primate and murine TIM receptors but they are absent in Tim-2 (Fig. ID), which has a unique CC'-loop conformation.
  • the loops connecting the C and C ⁇ -strands are largely divergent both in length and conformation among V domains of IgSF receptors (37).
  • the CC'-loop in the TIMs is seven residues longer than in the structurally related CD4 receptor and it has similar length but different conformation than in the homologous CAR domain (see Fig. 2C).
  • the CC'-loop adopts an extended conformation, similar to the IgV domains ⁇ vhere the GFC ⁇ -sheet is engaged in ligand recognition (16, 20, 41, 44), whereas in the TIM and CEA V domains the loop turns up onto the ⁇ -sheet (Fig. 2C).
  • a unique characteristic of the TIM receptors is that the folded CC'-loop is fixed by two external disulphide bonds that bridge it to the GFC ⁇ -sheet.
  • the CC'-loop in the TIMs reduces the accessibility of the GFC ⁇ - sheet, which functions as a ligand binding surface in related IgSF receptors (20, 41, 43). Therefore, it is likely that the TIM receptors use the CC'-loop instead of the ⁇ -sheet for binding to their ligands, as described for binding of the CEA receptor to coronaviruses
  • Tim-2 IgV domains self-associate at high protein concentration (Supplementary Fig. 1) and build up the asymmetric unit of the crystals (Fig. 3A).
  • the angle between the two Tim-2 domains is around 60° (Fig. 3A), similar to intermolecular angles reported in structures showing dimerization in cis of receptors linked to the same cell surface (4).
  • Main intermolecular contacts include residues following the ⁇ -strand B, such as the conserved Pro 15, the helical BC and CC loops from the two interacting molecules and residues on the FG-loop and upper half of the ⁇ -strand G (Fig. 3D).
  • the His97 residue that begins the ⁇ -strand G is about the centre of the dimer interface (labelled in Fig. 3 A and blue in Fig. 3D).
  • the hydrophobic cavity below the His97 side chain is occupied by an acetyl ligand, hydrogen bonded to the two neighbouring histidine residues (black in Fig. 3 A and Supplementary Fig. 2), while a network of water molecules hydrogen bonded to main chain oxygen atoms fill up the cavity over the His97 residue (Fig. 3A). Almost
  • Tim-4 The structure of the IgV domain of murine Tim-4 (Fig. 7A) was resolved similarly to that of Tim-1. Interestingly, in the Tim-4 crystals the IgV domains do not form intermolecular interactions as seen in the Tim-1 and Tim-2 crystals, and it is presented as a monomeric unit. This arrangement of the IgV domain indicated that the Cys-rich domain of Tim-4 does not form homophilic interactions and most likely do not interact with IgV domains of other TIM family members to form heterophilic interactions.
  • the structure of the IgV domain of Tim-4 is highly similar to the IgV domain of Tim-1 described herein with some conformational flexibility in the BC and FG loops, particularly in the case on the BC-loop, which is quite flat in the Tim-4 structure.
  • the characteristic CC'-loop of the TIM family shows a conserved conformation between the two structures (Fig. 7B).
  • Fig. 7B The characteristic CC'-loop of the TIM family shows a conserved conformation between the two structures.
  • Fig. 7B There are also striking differences in the conformation of the conserved Phe residue in the FG-loop. While in Tim-1 the Phe has a unique conformation and extends toward the CC'-loop, in Tim-4 the residue adopts two different conformations (Fig 7B). In one conformation (closed, dark blue) the side chain of the Phe residue inserts occupies a cavity between the FG and CC loops, while in the other conformation (open, light blue) it projects toward the top of the domain.
  • Tim-4 structure defined a ligand binding pocket in the N-terminal IgV domain of TIMs.
  • TLA tartrate
  • F95 residue adopted the open conformation defined by the Tim-4 structure (Fig. 8A), so that the cavity was empty and free for ligand binding.
  • the TLA molecule was bound to an ion found coordinated to residues at the FG-loop (Fig 8B) with the F95 in an open conformation.
  • the modeled potasium ion (K) was coordinated to the main chain
  • Tim-1, Tim-2 and Tim-4 were prepared with the program MODELLER, based on the Tim-1 crystal structure and sequence alignment presented in Fig. 1.
  • the superimposed IgV structures of Tim-1, Tim-2 and Tim-4 with the model of Tim-3 (Fig. 9) show that they adopt a highly similar IgV domain with conformational variability in BC, FG and CC loops.
  • the characteristic CC'-loop of the TIM family adopts a distinct conformation between the Tim-1 and Tim-2 structures, while the structure of the loop in Tim-1, Tim-3 and Tim-4 is very similar.
  • Fig. 10 The models of the human TIM family members (Fig. 10) were prepared with the program MODELLER, based on the Tim-1 crystal structure and sequence alignment presented in Fig. 1. As supported by the superimposed Tim-1 and Tim-4 crystal structures (Fig. 7B), the largest structural varibility of the human TIM family members is at the BC- loop, where there are some differences in the loop length among the TIM gene family. We would expect some structural variability in the FG-loop, particularly related to the type of ligand bound to the TTM domain. In contrast we expect conservation in the conformation of the long CC'-loop found in the TIM receptors.
  • Clarified cell supernatants collected from cells transfected with the vector (mock) or the recombinant pEF-Tim-HA constructs were incubated with or without 5 mM of BS3 ((Bis(sulfosuccinimidyl) suberate) (Pierce) overnight at 4°C. The reaction was quenched using 50 mM Tris pH 7.5 and incubated for 20 min at room temperature. Proteins were immunoprecipitated with anti-HA mAb and protein A-Sepharose, resolved by 8% SDS- PAGE under reducing conditions and transferred to a Hybond-P PVDF membrane (Amersham Biosciencies).
  • HA-tagged proteins were detected by immunoblot with the anti-HA mAb and the ECL detection system (Amersham Biosciences).
  • Cell supernatants having the Tim-2-HA receptor were used for chromatography analysis of receptor oligomerization. Supernatants were concentrated five times and run through a Supedex200 column with HBS buffer (20 mM Hepes and 100 mM NaCl, pH 7.5). The Tim-2-HA protein in the elution fractions was detected by ELISA with the anti-HA mAb. Molecular weight markers were run under the same conditions.
  • Binding of soluble Fc fusion proteins to plastic coated IgV domain prepared in bacteria and Tim- 1 -HA protein prepared in mammalian cells was carried in duplicate wells of 96-well plates as described elsewhere (14).
  • a control ICAM-I-Fc (IC1-2D) protein was included in the experiments.
  • Soluble Fc fusion protein supernatants were supplemented with 5% FCS and diluted with binding buffer (20 mM Tris pH 7.5, 100 mM NaCl, 2.5 mM CaCl 2 , and 1% BSA) at the indicated concentration. Binding of the Fc protein was monitored by OD at 492 nm (14). Blocking antibodies were used at 30 ⁇ g/ml.
  • Protein A purified Fc fusion proteins were covalently coupled to 6 micron blue carboxylated microparticles using the carbodiimide kit as recommended by the manufacturers (Polyscience, Inc.).
  • the poliovirus receptor (PVR) protein was included as control. 293H cells transfected with the plasmids containing cDNAs coding for the
  • Tim-2 dimer structure To confirm the relevance of the Tim-2 dimer structure and the organization of the Tim-2 receptor on the cell surface, we analyzed oligomerization of the complete extracellular region (IgV and mucin regions) of the receptor molecule.
  • Cell supernatants containing soluble Tim receptors tagged with a HA epitope were treated with the BS3 crossl inker and analyzed by SDS-PAGE as described in Materials and methods (Fig. 3C). Since the experiment was done under non-saturating crosslinker concentration, most of the receptor molecules migrated as monomer (40 kD) in the denaturing gel.
  • Tim-2 receptor oligomers having molecular weights around 80, 120 and 150 IcD were seen in the BS3 treated Tim-2 supernatants (arrows in Fig. 3C).
  • Tim-1 did not oligomerize under the same conditions, suggesting that this receptor must be expressed as a monomer on the cell surface.
  • Heterogeneity related to O and N-linked glycosylation could account for the broad bands of the soluble Tim proteins.
  • To further characterize Tim-2 oligomers poorly resolved in the electrophoresis we applied size exclusion chromatography in the absence of crosslinker (Fig. 4). This technique confirmed stable oligomerization of the Tim-2 receptor and identified tetrameric receptor forms (about 160 kD).
  • Tim-2 The amount of monomer varied with the experimental conditions, indicating it might come from dissociation of Tim-2 oligomers. Since the isolated N- terminal IgV domain of Tim-2 dimerizes in the crystals and in solution (Fig3), it appears that the formation of larger Tim-2 oligomers requires the mucin domain, Homophilic TIM-TIM receptor interaction in the Tim-1 crystal structure. [0070] As shown for Tim-2 and differing from Tim-4, Tim-1 IgV domain dimerization was observed by chemical crosslinking at high protein concentration in solution . However, the association of the two Tim-1 domains in the asymmetric unit of the crystals was remarkably different from the Tim-2 structure (Fig. 3). In the Tim-1 crystals the two domains are related by a rotation angle of about 180° and have their C-terminal ends extending toward opposite directions (Fig. 3B), which is suggestive of an intermolecular
  • Tim-1 Although intercellular high affinity binding of Tim-1 to Tim-4 has been described in the past (30), our results are the first indication of homophilic binding in the TIM family. To analyze the relevance of this interaction both protein and cell binding assays were performed (Fig. 5). Binding of a soluble Tim-l-Fc fusion protein to plastic coated Tim-1 proteins having either the isolated IgV domain used in crystallization or the complete extracellular region of the receptor was assessed by protein-protein-binding assay (Figs. 5A, 5B), showing Tim 1 -Tim 1 binding through the N-terminal IgV domain.
  • Tim-2-Fc fusion protein did not bind to either Tim-1 (Figs. 5 A, 5B) or Tim-2 proteins. Homophilic Tim-1 binding was specifically blocked by the Tl .10 mAb that recognizes the IgSF domain and by the addition of EDTA (Fig. 5C), which indicates a requirement of divalent cations for high affinity binding and suggests involvement of carbohydrates from the mucin domain. Interestingly, the mutation His64/Glu in the soluble Tim-1 -Fc protein significantly reduced its binding to Tim-1 proteins on plates (Fig. 5C), showing a critical contribution of the DE-loop to the homophilic interaction revealed by the Tim-1 structure (Fig.3B).
  • Tim-1 -Fc bound to cell surface expressed Tim-1 and this interaction was blocked by the Tl .10 mAb.
  • beads coated with the human TIM-I -Fc protein also bound specifically to TIM-1 receptor expressed on the surface of 293 cells (Fig. 5D), showing that this homophilic adhesion interaction is conserved in mice and humans. Homophilic TIM-1 binding required both IgV and mucin domains.
  • EXAMPLE 3 IDENTIFICATION OF LIGAND BINDING SURFACES [0073] Based on the structure of the TIM family members, at least five areas have been defined as major targets for ligands that will act as agonists or antagonists of TIM family member interactions. The five areas described below are defined by surface residues depicted in Figure 1 1 A on the structure of Tim-1 taken as an example of all TIM family members. The corresponding residues in the other murine and human TIM family members are defined in the alignment of the corresponding sequences in Figure 1 1 B. The 5 defined surface areas for interactions are:
  • Area 1 defined by CC and FG loops. Binding of cations such as Ca++ and K+ and binding of potasium tartrate in Tim-4. This cavity is similar to one found in lectins that allows binding of sugars. This cavity can accommodate binding of a small molecule that could inhibit binding of natural ligands, such as IgA to Tim-1 or TIM-1, by restricting movement of FG loop needed for homophilic interaction and interaction with IgA. This surface is also the binding site for HAV (protective mAb 190/4 binds to the blue spot shown in Figure 1 I A).
  • Area 3 defined by the BED B-sheet and adjacent loops. The long FG loop interacts with this region if it is not fixed to the CC loop by a compound locking the cavity formed by the FG and CC loops (area 1). This area is where homophilic, and most likely IgA and other heterophilic interactions occur. Small molecules that bind to this area could stabilize interactions such as cell adhesion and activation of APCs. mAbs to this area could prevent adhesion, and tumor development.
  • Area 4 the channel defined by the ⁇ -strand A at the bottom, the ⁇ -strand G at one side, and the ⁇ -barrel edge at the other side. On top, the channel is limited by the BC and FG loops. A mucin tail is likely to bind to this channel. The mucin is needed for uncoating of HAV, and alleles with longer mucins are protective against asthma. Therefore, small molecules that prevent binding of the mucin will prevent virus infection and enhance Th2 responses, and molecules that enhance binding of mucin could prevent asthma and atopy.
  • Area 5 defined by the CC" loop (in green). This is the binding site for galactin-9 in Tim-3. Binding of small molecules and mAbs will block interaction with natural ligands and modulate ThI responses.
  • the top face of the N-terminal Tim-2 domain dimer complements well in shape with the concave ligand binding surface defined by a Semaphorin dimer structure (not shown) (25).
  • receptor oligomerization through the mucin domain on the cell surface would facilitate multivalent binding and subsequent endocytosis of the large H-ferritin polymer (24).
  • the observed role of the mucin domain in self-association of the Tim-2 receptor on the cell surface is likely to be shared by other TIM receptor molecules and have some influence on their ligand recognition specificities. Polymorphisms in the mucin domain might then affect receptor oligomerization and function.
  • Tim-2 dimerization of the N-terminal domain of Tim-2 buries the domain surface engaged in homophilic Tim-1 interactions (Fig. 3, 6), preventing Tim-2 binding to Tim-1 as well as homophilic Tim-2 binding (Fig 5). Preliminary observations showed that disruption of the Tim-2 dimer allowed binding to Tim-1 ).
  • HAV specifically binds to the N-terminal domain of the human and monkey TIM- 1 receptors (HAVCRl /TIM-I) (9, 18), while no binding to mouse Tim-1 has been detected (Kaplan et al., unpublished results).
  • the expected structural similarity between the primate and mouse N-terminal domains allowed us to define a virus binding surface based on a gene polymorphism in monkey HAVCRl/TIM-1 that abolished binding of a protective mAb (190/4) (8) (Fig. 6B).
  • the antibody blocks HAV receptor binding and protects cells from infection.
  • the antigenic variant (Lys/Gln) aligns with Glu90 in Tim-1 (Fig.
  • the conservation of the FG-loop between the primate and mouse TIM-1 receptors indicate that the enhanced hydrophobicity of the CC'-loop in HAVCRl/TIM-1 could determine its virus binding specificity (Fig. ID).
  • the unique Phe residue in the primate receptors at the Ser37 position of the Tim-1 CC'-loop could in fact be a critical virus binding residue, as described for a hydrophobic residue at the homologous loop in the CEA coronavirus receptor (37).
  • receptor oligomerization through the long mucin domains of the human and monkey TIM-1 could facilitate multimeric HAV receptor binding and subsequent cell entry.
  • Tim-1 The crystal structure of Tim-1 identified a new homophilic TIM-TIM receptor interaction that is conserved in mice and humans and is likely relevant for the regulation of
  • Tim-1 signalling to T cells could explain the reported role of B cells in optimization of T cell expansion and generation of memory and effector T cells (7).
  • the conservation of the homophilic Tim-1 receptor interaction both in mice and humans supports a conserved role in B-T cell cross-talk and its relevance in the immune system. [0085]
  • the homophilic Tim-1 IgV domain binding pictured by the crystal structure revealed a striking difference to those mediated by related IgSF receptors.
  • Tim-1 IgV domains contact through their BED faces, opposite to the ligand binding GFC face in IgSF receptors (16, 20, 41 , 43), which is covered in Tim-1 by the CCVFG epitope (Fig. 3B, 6B).
  • a mutation (His64/Glu) at the DE-loop of Tim-1 affected significantly the homophilic Tim-1 interaction (Fig. 5C), confirming the relevance of the structure and suggesting a critical contribution of the loop to the binding interaction.
  • homophilic binding engages the N-terminal IgV domain
  • experiments shown in Figure 4 suggest that carbohydrates from the contiguous mucin domain also contribute to the interaction.
  • O-linked glycosylation sites are close to the C-terminal end of the IgV domain in most TIMs (21 , 27), particularly in the TIM-4 receptors.
  • O-linked glycans from the mucin domain could participate in intercellular interactions among TIM receptors by occupying cavities generated upon N-terminal domain binding, such as that seen between the interacting Tim-1 domains.
  • the cavity between ⁇ -strand A and FG-loop of two interacting Tim-1 IgV domains defines a potential glycan interacting site, having amino acid residues found at glycan-recognition sites of lectins (45).
  • polymorphisms in the mucin domain near the end of the IgV domain (27) might have also
  • EXAMPLE 4 TARGETING MUTATIONS BASED ON THE STRUCTURE OF TIM FAMILY MEMBERS
  • TIM family members were utilized to target mutations that induce changes in the homophilic and heterophilic interactions of these receptors.
  • the mouse Tim-1, mouse Tim-2 and the human HAVCR1/TIM1 were mutated and the effect of the mutations was assessed biochemically.
  • the targeted mutations produced have a pronounced effect in the behavior of the TIM family of receptors.
  • the BC loop an important loop for the homophilic interactions of mouse Tim-1 (Area 3, see Figure 1 IA), was mutated and homophilic interactions were analyzed by binding soluble Tim-1 -Fc fusion protein to Tim-1 IgV protein coated onto 96-well plates.
  • Tim-1 His64/Glu 5 '-TTAAAGGGGGAAATTTCAGAAGGA-S ' , and the construct was termed Tim-1 His64/Glu.
  • cDNAs coding for the complete extracellular region of the Tim-1 or the Tim-1 His64/Glu mutant followed by a thrombin recognition site were cloned upstream of the IgGl -Fc (Fc) region in the pEF-BOS expression vector (15).
  • Serum free cell supernatants containing the Fc tagged soluble receptor proteins were prepared by transient expression in 293T cells. Supernatants were concentrated using Amicon 100 filters until the concentration of the Fc fusion proteins reached about 50 ⁇ g/ml and determined by a sandwich ELISA (15).
  • INCORPORATED BY REFERENCE (RULE 20.6) constructed: the Arg65/Glu mutant containing a GIu residue at position 65, and the DEtI mutant containing the double mutation Asp62/His and Arg65/Glu. Overlapping PCR technique with the Pfu I polymerase was used to construct the mutants. The Arg65/Glu mutant was contructed using mutagenic oligonucleotide
  • mutation in the BC-loop predicted to be an important area for homophilic interactions of TIM family members can result in an increase or decrease in homophilic interactions. Consequently, mutation in the BC-loop will increase or reduce cell adhesion and influence homophilic and heterophilic interactions.
  • Tim-2 required for the formation of dimers was mutated to resemble the Tim-1 loop.
  • the mutation in the IgV domain of Tim-2 was introduced by verlapping PCR technique with the Pfu I polymerase using oligonuceleotide T2-BCtl .D
  • the structure of the TIM family members predicted that the interaction of the CC with FG loops (Area 1 , see Figure 1 IA) modulates the accessibility of the FG-loop and conformation of the BC-loop.
  • the CC-loop of TIMl was mutated by swapping amino acids SLFT found between the 3 rd and 4 n Cys residues of TIMl for amino acids residues PYSG found in the same positions of human TIM4. Binding of IgA to the mutated TIMl was then assessed.
  • the TIMl mutant was prepared by overlapping PCR using the mutagenic oligonucleotide 5 '-TGTCCCTACTCCGGTTGCCAAAATGGCATTGTCTGGACC-S ' . The resulting
  • PCR fragment was cloned into the cDNA of TIMl-Fc, and the resulting mutant was termed TIMl(Cys3-4)-Fc.
  • the sequence of the mutant was verified by automatic nucleotide sequence analysis.
  • CHO dhfr- cells were cotransfected with the TIMl(Cys3- 4)-Fc plasmid and a plasmid coding for the DHFR gene.
  • CHO cell transfectants were selected in Iscove's media, and the expression of TIMl (Cys3-4)-Fc was optimized with increasing concentrations of methotrexate.
  • the TIMl(Cys3-4)-Fc protein was purified from the supernatants of the CHO transfectants using chromatography in protein A columns.
  • TIMl -Fc or TIMl (Cys3-4)-Fc were captured on 96-well plates (Nunc, Inc.) coated with 1 ⁇ g/ml goat anti-human Fc .
  • Human secretory IgA (starting at 1 ⁇ g/ml) was titrated on the plates and stained with peroxidase-labeled anti-human IgA and One- Component TMB. Absorbance at 450 nm was determined in an ELISA plate reader. This in vitro binding assay clearly showed that TIMl (Cys3-4)-Fc did not bind IgA.
  • Kidney Injury Molecule- 1 a Putative Adhesion Protein Involved in Renal Regeneration. J. Biol. Chem. 277:39739-39748.
  • TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med 202:955-65.
  • Kidney Injury Molecule- 1 (KIM-I): a novel biomarker for human renal proximal tubule injury. Kidney Int 62:237-44.
  • T Cell Ig- and mucin- domain-containing molecule-3 (TIM-3) and TIM-I molecules are differentially expressed on human ThI and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis. J Immunol 172:7169-76.
  • junctional adhesion molecule structural basis for homophilic adhesion via a novel dimerization motif.
  • TIM-4 is the ligand for TIM-I , and the TIM-l -TIM-4 interaction regulates T cell proliferation. Nat Immunol 6:455-64.
  • HAV hepatitis A virus
  • ATOM 24 CA TYR A 4 -1. 131 27, .346 15 .927 1 .00 44. 50 A
  • ATOM 61 CG LYS A 8 10. 458 23. 474 18. 345 1. 00 21. 37 A ATOM 62 CO LYS A B 10.687 24.052 19.726 1.00 23.09
  • ATOM 102 CB PRO A 14 11. ,247 10 ,818 12 ,191 1 .00 25 .17
  • ATOM 140 SG CYS A 19 4. 833 16, 879 12 ,858 1, 00 22 .73
  • ATOM 180 CE2 TYR A 24 -17 .718 13 .626 17 .801 1 ,00 22 .45
  • ATOM 186 CA ARG A 25 -19. .596 9 .925 15 .034 1 .00 26 .21 A
  • ATOM 236 CA TRP A 32 -2 .573 17 .435 5.031 1 .00 20 .13
  • ATOM 266 C GLY A 35 -0 .127 26 .318 5 .334 1 .00 28 .76
  • ATOM 269 CA GLN A 36 -1. .715 27 .601 6 .660 1 .00 31 .48
  • ATOM 272 CD GLN A 36 -3. .096 30. ,816 8 .344 1. ,00 39, , 04
  • ATOM 278 CA CYS A 37 -5. 263 26. 138 6 .531 1. 00 34, 54
  • ATOM 282 SG CYS A 37 485 23. 902 8 .375 1. 00 32. 57
  • ATOM 308 CA CYS A 42 -5.555 21.601 2.035 1.00 36,67
  • ATOM 328 C ASN A 44 -O .216 20. ,922 -0 .581 1. ,00 33, ,01
  • ATOM 331 CA THR A 45 .635 18. 941 -0. 312 1. 00 26. 57
  • ATOM 346 CA ILE A 47 -1 .727 13 ,696 2.220 1 .00 15 .91
  • ATOM 383 CA GLY A 51 -10, 763 7.090 6.508 1. .00 22, .62
  • ATOM 400 CD ARG A 53 -6 .498 1 .515 2 .763 1 .00 35 .79
  • ATOM 404 NH2 ARG A 53 ⁇ 10 .037 0 .932 3 .574 1 .00 40 .38

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des structures cristallines du domaine de liaison à un ligand de type Ig riche en Cys N-terminal des récepteurs Tim-1, Tim-2 et Tim-4 murins et des modèles pour le récepteur Tim-3 murin et les récepteurs HAVCR1/TIM1, TM3 et TIM4 humains basés sur lesdites structures cristallines, et concerne également des matériaux et procédés pour identifier des mimétiques des ligands naturels pour ces récepteurs et également des antagonistes de ces ligands. Les structures révèlent également une interaction homophile pour chaque récepteur, qui est biochimiquement confirmée. Cette invention concerne des matériaux et des procédés pour cibler des mutations spécifiques sur les récepteurs de la famille TIM sur la base de leur structure cristalline pour moduler (améliorer, réduire ou inhiber) des interactions homophiles et/ou hétérophiles ainsi qu'une liaison à des ligands naturels. Les mutants récepteurs de TIM résultants pourraient être utilisés en tant qu'agents thérapeutiques. Ainsi, l'invention concerne également des matériaux et des procédés pour identifier des agonistes et des antagonistes d'interactions homophile et hétérophile d'éléments de la famille TIM. HAVCR1/TIM1 est le récepteur pour le virus de l'hépatite A (HAV), et ainsi l'invention concerne également des matériaux et des procédés pour identifier des inhibiteurs de l'infection par le HAV.
PCT/US2007/084601 2007-11-13 2007-11-13 Structure d'éléments de la famille tim WO2009064290A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86564207P 2007-11-13 2007-11-13
US60/865,642 2007-11-13

Publications (1)

Publication Number Publication Date
WO2009064290A1 true WO2009064290A1 (fr) 2009-05-22

Family

ID=39816664

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/084601 WO2009064290A1 (fr) 2007-11-13 2007-11-13 Structure d'éléments de la famille tim

Country Status (1)

Country Link
WO (1) WO2009064290A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10639368B2 (en) 2016-05-27 2020-05-05 Agenus Inc. Anti-TIM-3 antibodies and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099955A1 (en) * 1999-05-13 2003-05-29 Wimberly Brian T. Crystal structure of ribosomal protein L11/GTPase activating region rRNA and uses thereof
WO2004084823A2 (fr) * 2003-03-19 2004-10-07 Abgenix, Inc. Anticorps contre l'antigene de lymphocytes t, du domaine d'immunoglobuline et du domaine 1 de mucine (tim-1) et leurs utilisations
WO2005027854A2 (fr) * 2003-09-15 2005-03-31 The Board Of Trustees Of The Leland Stanford Junior University Genes regulateurs des lymphocytes t associes a une maladie immune
WO2005090573A2 (fr) * 2004-03-12 2005-09-29 The Brigham And Women's Hospital, Inc. Procedes de modulation de reponses immunitaires par la modulation de la fonction tim-1, tim-2 and tim-4
WO2005097211A2 (fr) * 2004-03-24 2005-10-20 Telos Pharmaceuticals, Inc. Compositions adjuvantes ameliorant la reponse immunitaire a des vaccins et methodes d'utilisation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099955A1 (en) * 1999-05-13 2003-05-29 Wimberly Brian T. Crystal structure of ribosomal protein L11/GTPase activating region rRNA and uses thereof
WO2004084823A2 (fr) * 2003-03-19 2004-10-07 Abgenix, Inc. Anticorps contre l'antigene de lymphocytes t, du domaine d'immunoglobuline et du domaine 1 de mucine (tim-1) et leurs utilisations
WO2005027854A2 (fr) * 2003-09-15 2005-03-31 The Board Of Trustees Of The Leland Stanford Junior University Genes regulateurs des lymphocytes t associes a une maladie immune
WO2005090573A2 (fr) * 2004-03-12 2005-09-29 The Brigham And Women's Hospital, Inc. Procedes de modulation de reponses immunitaires par la modulation de la fonction tim-1, tim-2 and tim-4
WO2005097211A2 (fr) * 2004-03-24 2005-10-20 Telos Pharmaceuticals, Inc. Compositions adjuvantes ameliorant la reponse immunitaire a des vaccins et methodes d'utilisation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAO ERHU ET AL: "T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface", IMMUNITY, vol. 26, no. 3, March 2007 (2007-03-01), pages 311 - 321, XP002500151, ISSN: 1074-7613 *
SANTIAGO CESAR ET AL: "Structures of T cell immunoglobulin mucin receptors 1 and 2 reveal mechanisms for regulation of immune responses by the TIM receptor family", IMMUNITY, vol. 26, no. 3, March 2007 (2007-03-01), pages 299 - 310, XP002500150, ISSN: 1074-7613 *
TAMI CECILIA ET AL: "Immunoglobulin A (IgA) is a natural ligand of hepatitis A virus cellular receptor 1 (HAVCR1), and the association of IgA with HAVCR1 enhances virus-receptor interactions.", April 2007, JOURNAL OF VIROLOGY APR 2007, VOL. 81, NR. 7, PAGE(S) 3437 - 3446, ISSN: 0022-538X, XP002500152 *
THOMPSON PETER ET AL: "The Cys-rich region of hepatitis A virus cellular receptor 1 is required for binding of hepatitis A virus and protective monoclonal antibody 190/4", JOURNAL OF VIROLOGY, vol. 72, no. 5, March 1998 (1998-03-01), pages 3751 - 3761, XP002514053, ISSN: 0022-538X *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10639368B2 (en) 2016-05-27 2020-05-05 Agenus Inc. Anti-TIM-3 antibodies and methods of use thereof
US10912828B2 (en) 2016-05-27 2021-02-09 Agenus Inc. Anti-TIM-3 antibodies and methods of use thereof
US11839653B2 (en) 2016-05-27 2023-12-12 Agenus Inc. Anti-TIM-3 antibodies and methods of use thereof
US12011481B2 (en) 2016-05-27 2024-06-18 Agenus Inc. Anti-TIM-3 antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
CA2465268A1 (fr) Structures tridimensionnelles de tall-1 et de ses recepteurs parents, proteines modifiees et procedes associes
AU2009201692B2 (en) Binding moieties based on shark IgNAR domains
Rossjohn et al. Structure of the activation domain of the GM-CSF/IL-3/IL-5 receptor common β-chain bound to an antagonist
US6820011B2 (en) Three-dimensional structure of complement receptor type 2 and uses thereof
Crawford et al. Structural characterization of apical membrane antigen 1 (AMA1) from Toxoplasma gondii
Iyer et al. The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 Å resolution
Li et al. Crystal structure of a dimerized cockroach allergen Bla g 2 complexed with a monoclonal antibody
JP2005517227A (ja) サイトカイン受容体
Watson et al. The crystal structure and mutational binding analysis of the extracellular domain of the platelet-activating receptor CLEC-2
WO2008021379A2 (fr) Activité et efficacité accrues de proteins de type expansine
CA2782481A1 (fr) Structure cocristalline de facteur d et anticorps anti-facteur d
OA10786A (en) Method of inhibiting cathepsin k
Batuwangala et al. Structure of the snake-venom toxin convulxin
Al-Shar'i et al. Molecular dynamics simulations of adenosine receptors: Advances, applications and trends
US20100248974A1 (en) Crystal structure of cd147 extracellular region and use thereof
Deka et al. Crystal structure of the Tp34 (TP0971) lipoprotein of Treponema pallidum: implications of its metal-bound state and affinity for human lactoferrin
Horii et al. Crystal structure of EMS16 in complex with the integrin α2-I domain
Evans et al. Crystal structure and binding properties of the CD2 and CD244 (2B4)-binding protein, CD48
WO2009064290A1 (fr) Structure d'éléments de la famille tim
Klein et al. The receptor binding site of human interleukin-3 defined by mutagenesis and molecular modeling
AU2648800A (en) Cytokine-binding domain
Staelens et al. Paratope determination of the antithrombotic antibody 82D6A3 based on the crystal structure of its complex with the von Willebrand factor A3-domain
WO2009131572A1 (fr) Structure de membres de la famille tim
Wang et al. Structural insight into the kinetics and ΔCp of interactions between TEM-1 β-lactamase and β-lactamase inhibitory protein (BLIP)
CA2588273A1 (fr) Pharmacophores pf4 et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07872814

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07872814

Country of ref document: EP

Kind code of ref document: A1